{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:56:42Z","timestamp":1792519002650,"version":"4.5.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T00:00:00Z","timestamp":1696550400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,6]]},"abstract":"<jats:p>Raltegravir and other third-line drugs have shown promise in improving outcomes in treatment-experienced patients. However, the efficacy and tolerability of these agents vary. This study assessed real-life virologic success, long-term survival, and adverse events in patients receiving raltegravir or other third-line drugs as salvage regimens. This retrospective cohort study included adults who experienced treatment failure (human immunodeficiency syndrome-1 RNA plasma viral load\u2005&gt;1000 copies\/mL) and subsequently initiated raltegravir or other third-line drugs (darunavir\/ritonavir, maraviroc, or etravirine). Propensity score matching methods were employed to account for differences at the time of switching from failing antiretroviral therapy regimens. The matched subset was analyzed using the Kaplan\u2013Meier method and Generalized Wilcoxon tests to evaluate the probability of achieving virologic suppression (plasma viral load\u2005&lt;50 copies\/mL). Mortality rates, toxicity, treatment interruption, virologic failure, and loss to follow-up were determined using Poisson regression. One hundred and sixty-eight patients initiating salvage regimens were included, with 123 receiving raltegravir and 45 other third-line drugs. Propensity score matching resulted in a subset of 90 patients, 45 in each group. During the follow-up period, there were no significant differences observed between the groups in terms of virologic suppression (77.8% vs 82.2%, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.73), mortality rates (4.04 vs 6.18 persons per 100 person-years [p-y]; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.67), drug toxicity (0.00 vs 2.06 persons per 100 p-y; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.49), treatment interruption (8.07 vs 0.00 persons per 100 p-y; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.06), virologic failure (2.02 vs 4.12 persons per 100 p-y; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.61), and loss of follow-up (6.05 vs 4.12 persons per 100 p-y; <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.70). Our findings indicate comparable survival and virological success rates between raltegravir and other drugs used in salvage regimens. Similar rates of drug toxicity, treatment interruption, virologic failure, and loss of follow-up were also observed. These results suggest that raltegravir may be a viable option for salvage therapy, demonstrating outcomes comparable to other third-line drugs in real life.<\/jats:p>","DOI":"10.1097\/md.0000000000035407","type":"journal-article","created":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T12:08:47Z","timestamp":1696594127000},"page":"e35407","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Long-term outcomes of highly experienced people with HIV undergoing salvage therapy with raltegravir"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2948-5550","authenticated-orcid":false,"given":"Jes\u00fas Enrique","family":"Pati\u00f1o Escarcina","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Federal University of Bahia, Salvador, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Martins","family":"Netto","sequence":"additional","affiliation":[{"name":"LAPI - Infectious Disease Research Laboratory, Complexo Hospitalar Universit\u00e1rio Profesor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Brites","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Federal University of Bahia, Salvador, Brazil"},{"name":"LAPI - Infectious Disease Research Laboratory, Complexo Hospitalar Universit\u00e1rio Profesor Edgard Santos, Universidade Federal da Bahia, Salvador, Brazil."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1001\/jama.2018.8431","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults.","volume":"320","author":"Saag","year":"2018","journal-title":"JAMA"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/infdis\/jiw085","article-title":"Incidence of AIDS-defining opportunistic infections in a multicohort analysis of HIV-infected persons in the United States and Canada, 2000\u20132010.","volume":"214","author":"Buchacz","year":"2016","journal-title":"J Infect Dis"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/314623","article-title":"Combination antiretroviral therapy and recent declines in AIDS incidence and mortality.","volume":"179","author":"Vittinghoff","year":"1999","journal-title":"J Infect Dis"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2174\/157016211798038533","article-title":"Modelling the impact of antiretroviral therapy on the epidemic of HIV.","volume":"9","author":"Williams","year":"2011","journal-title":"Curr HIV Res"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1590\/S1020-49892012000800005","article-title":"Impacto da terapia antirretroviral conforme diferentes consensos de tratamento da Aids no Brasil.","volume":"32","author":"Rossi","year":"2012","journal-title":"Rev Panam Salud P\u00fablica"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2471\/BLT.12.112946","article-title":"Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review.","volume":"91","author":"McMahon","year":"2013","journal-title":"Bull World Health Organ"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"e0174767","DOI":"10.1371\/journal.pone.0174767","article-title":"Virological success after 12 and 24 months of antiretroviral therapy in sub-Saharan Africa: comparing results of trials, cohorts and cross-sectional studies using a systematic review and meta-analysis. Kaul R, ed.","volume":"12","author":"Taieb","year":"2017","journal-title":"PLoS One"},{"key":"R11-20250504","first-page":"23","article-title":"Management of HIV infection after triple class failure.","volume":"36","author":"Cossarini","year":"2013","journal-title":"New Microbiol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e588","DOI":"10.1016\/S2352-3018(18)30173-5","article-title":"HIV drug resistance in low-income and middle-income countries.","volume":"5","author":"Hamers","year":"2018","journal-title":"Lancet HIV"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1756-0500-6-512","article-title":"Trends in mortality and loss to follow-up in HIV care at the Nkongsamba Regional hospital, Cameroon.","volume":"6","author":"Bekolo","year":"2013","journal-title":"BMC Res Notes"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e356","DOI":"10.1371\/journal.pmed.0030356","article-title":"Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART. Lane HC, ed.","volume":"3","author":"Hogg","year":"2006","journal-title":"PLoS Med"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"62","DOI":"10.5582\/bst.2016.01195","article-title":"Trends and characteristics of all-cause mortality among HIV-infected inpatients during the HAART era (2006-2015) in Shanghai, China.","volume":"11","author":"Ji","year":"2017","journal-title":"Biosci Trends"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"990","DOI":"10.3346\/jkms.2013.28.7.990","article-title":"Causes of death and risk factors for mortality among HIV-infected patients receiving antiretroviral therapy in Korea.","volume":"28","author":"Lee","year":"2013","journal-title":"J Korean Med Sci"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1473-3099(06)70550-3","article-title":"Approach to salvage antiretroviral therapy in heavily antiretroviral-experienced HIV-positive adults.","volume":"6","author":"Temesgen","year":"2006","journal-title":"Lancet Infect Dis"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"e3361","DOI":"10.1097\/MD.0000000000003361","article-title":"Adherence to antiretroviral therapy and virologic failure.","volume":"95","author":"Bezabhe","year":"2016","journal-title":"Medicine (Baltim)"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1186\/s13643-020-01524-1","article-title":"Factors associated with antiretroviral treatment failure among people living with HIV on antiretroviral therapy in resource-poor settings: a systematic review and meta analysis.","volume":"9","author":"Lailulo","year":"2020","journal-title":"Syst Rev"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1056\/NEJMoa035211","article-title":"Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia.","volume":"348","author":"Lazzarin","year":"2003","journal-title":"N Engl J Med"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1310\/hct1504-140","article-title":"Efficacy and safety of darunavir\/ritonavir plus etravirine dual regimen in antiretroviral therapy\u2013Experienced patients: a multicenter clinical experience.","volume":"15","author":"Gazzola","year":"2014","journal-title":"HIV Clin Trials"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1056\/NEJMoa0803152","article-title":"Maraviroc for previously treated patients with R5 HIV-1 infection.","volume":"359","author":"Gulick","year":"2008","journal-title":"N Engl J Med"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMoa0708975","article-title":"Raltegravir with optimized background therapy for resistant HIV-1 infection.","volume":"359","author":"Steigbigel","year":"2008","journal-title":"N Engl J Med"},{"key":"R24-20250504","first-page":"41","article-title":"The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.","volume":"13","author":"Hill","year":"2011","journal-title":"AIDS Rev"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1179\/1945577115Y.0000000001","article-title":"Regimen selection in the OPTIONS trial of HIV salvage therapy: drug resistance, prior therapy, and race\u2013ethnicity determine the degree of regimen complexity.","volume":"16","author":"Tashima","year":"2015","journal-title":"HIV Clin Trials"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"100002","DOI":"10.1016\/j.jve.2020.06.002","article-title":"HIV-1 resistance patterns to integrase inhibitors in Chilean patients with virological failure on raltegravir-containing regimens.","volume":"6","author":"Ferrer","year":"2020","journal-title":"J Virus Erad"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1473-3099(13)70093-8","article-title":"Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials.","volume":"13","author":"Eron","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1056\/NEJMoa0708978","article-title":"Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.","volume":"359","author":"Cooper","year":"2008","journal-title":"N Engl J Med"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1086\/650002","article-title":"Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-Experienced patients with drug-Resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 phase III trials.","volume":"50","author":"Steigbigel","year":"2010","journal-title":"Clin Infect Dis"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ijantimicag.2013.10.013","article-title":"Four years data of raltegravir-based salvage therapy in HIV-1-infected, treatment-experienced patients: the SALIR-E Study.","volume":"43","author":"Capetti","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1093\/infdis\/jir025","article-title":"HIV-1 integrase inhibitor resistance and its clinical implications.","volume":"203","author":"Blanco","year":"2011","journal-title":"J Infect Dis"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40268-017-0174-z","article-title":"Effectiveness and risk factors for virological outcome of raltegravir-based therapy for treatment-Experienced HIV-infected patients.","volume":"17","author":"Mata-Mar\u00edn","year":"2017","journal-title":"Drugs R D"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/QAI.0b013e31826cc592","article-title":"Patterns of adherence to raltegravir-based regimens and the risk of virological failure among HIV-infected patients.","volume":"61","author":"Gras","year":"2012","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000331998","article-title":"The HIVdb system for HIV-1 genotypic resistance interpretation.","volume":"55","author":"Tang","year":"2012","journal-title":"Intervirology"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/S0140-6736(17)32152-9","article-title":"Global, regional, and national age-sex specific mortality for 264 causes of death, 1980\u20132016: a systematic analysis for the Global Burden of Disease Study 2016.","volume":"390","author":"Naghavi","year":"2017","journal-title":"Lancet"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.cmpb.2003.10.004","article-title":"Adjusted survival curves with inverse probability weights.","volume":"75","author":"Cole","year":"2004","journal-title":"Comput Methods Programs Biomed"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1179\/1528433614Z.0000000019","article-title":"Long-term immunologic and virologic responses on raltegravir-containing regimens among ART-experienced participants in the HIV Outpatient Study.","volume":"16","author":"Buchacz","year":"2015","journal-title":"HIV Clin Trials"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1093\/jac\/dks254","article-title":"Risk factors for raltegravir resistance development in clinical practice.","volume":"67","author":"Malet","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/1469-0691.12100","article-title":"Factors associated with virological success with raltegravir-containing regimens and prevalence of raltegravir-resistance-associated mutations at failure in the ARCA database.","volume":"19","author":"Rusconi","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1468-1293.2009.00816.x","article-title":"History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change.","volume":"11","author":"Reekie","year":"2010","journal-title":"HIV Med"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/jmv.21500","article-title":"The relationship between genotypic sensitivity score and treatment outcomes in late stage HIV disease after supervised HAART.","volume":"81","author":"Castor","year":"2009","journal-title":"J Med Virol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1128\/AAC.01228-07","article-title":"Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.","volume":"52","author":"Malet","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/hiv.12692","article-title":"Prevalence and determinants of resistance mutations in HIV-1-infected patients exposed to integrase inhibitors in a large Italian cohort.","volume":"20","author":"Modica","year":"2019","journal-title":"HIV Med"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jgar.2019.07.015","article-title":"Evaluation of HIV-1 integrase resistance emergence and evolution in patients treated with integrase inhibitors.","volume":"20","author":"Scutari","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"R50-20250504","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12981-020-0262-y","article-title":"HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.","volume":"17","author":"Orta-Resendiz","year":"2020","journal-title":"AIDS Res Ther"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.1093\/jac\/dku190","article-title":"Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).","volume":"69","author":"Palella","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/QAI.0B013E31822D490A","article-title":"Depression and HIV\/AIDS treatment nonadherence: a review and meta-analysis.","volume":"58","author":"Gonzalez","year":"2011","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T03:05:45Z","timestamp":1746327945000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000035407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,6]]},"references-count":45,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000035407","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,6]]}}}